Literature DB >> 29739757

Evidence of Intertissue Differences in the DNA Damage Response and the Pro-oncogenic Role of NF-κB in Mice with Disengaged BRCA1-PALB2 Interaction.

Amar Hekmat Mahdi1,2, Yanying Huo1,2, Yongmei Tan1,2,3, Srilatha Simhadri1,4, Gabriele Vincelli1,2, Jie Gao3, Shridar Ganesan1,4, Bing Xia5,2.   

Abstract

The BRCA1-PALB2-BRCA2 axis plays an essential role in DNA homologous recombination repair, defect in which drives genome instability and cancer development. How cells with defects in this pathway respond to DNA damage in vivo and how tumors develop from these cells remain poorly defined. Here, we analyzed several aspects of the DNA damage response in multiple tissues of Palb2-mutant mice in which the interaction between PALB2 and BRCA1 is disengaged. Without any challenge, the mutant mice showed increased endogenous DNA damage. Following ionizing radiation, the mutant mice displayed higher levels of DNA breaks and stronger induction of p53 and p21, but continued DNA synthesis, reduced apoptosis, and accelerated tumor development. The differences in p21 induction, DNA synthesis, and apoptosis between wild-type and mutant mice were substantially more pronounced in the mammary gland than in the intestine, suggesting a potential contributing factor to the increased risk and the tissue specificity of BRCA/PALB2-associated tumor development. Moreover, the mutant mice showed higher levels of reactive oxygen species and constitutive activation of NF-κB, an antiapoptotic transcription factor inducible by both DNA damage and oxidative stress. Treatment of the mutant mice with an inhibitor of NF-κB reactivated apoptosis and delayed tumor development following radiation. Thus, our results also suggest a prosurvival and pro-oncogenic role of NF-κB in PALB2-mutant cells.Significance: This study explores novel tumor suppression mechanisms of the BRCA1-PALB2 DNA damage response pathway and implicates NF-κB activation as a protumorogenic event and possible therapeutic target. Cancer Res; 78(14); 3969-81. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29739757      PMCID: PMC6050088          DOI: 10.1158/0008-5472.CAN-18-0388

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

Authors:  Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

2.  Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.

Authors:  R Hakem; J L de la Pompa; A Elia; J Potter; T W Mak
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

3.  TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.

Authors:  Jing Nan; Yuping Du; Xing Chen; Qifeng Bai; Yuxin Wang; Xinxin Zhang; Ning Zhu; Jing Zhang; Jianwen Hou; Qin Wang; Jinbo Yang
Journal:  Mol Cancer Ther       Date:  2014-01-08       Impact factor: 6.261

Review 4.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.

Authors:  B Evers; J Jonkers
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

5.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

6.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.

Authors:  Sarah L Sawyer; Lei Tian; Marketta Kähkönen; Jeremy Schwartzentruber; Martin Kircher; Jacek Majewski; David A Dyment; A Micheil Innes; Kym M Boycott; Lisa A Moreau; Jukka S Moilanen; Roger A Greenberg
Journal:  Cancer Discov       Date:  2014-12-03       Impact factor: 39.397

7.  PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function.

Authors:  Jianglin Ma; Hong Cai; Tongde Wu; Bijan Sobhian; Yanying Huo; Allen Alcivar; Monal Mehta; Ka Lung Cheung; Shridar Ganesan; Ah-Ng Tony Kong; Donna D Zhang; Bing Xia
Journal:  Mol Cell Biol       Date:  2012-02-13       Impact factor: 4.272

8.  Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage.

Authors:  Andrea Sau; Rosanna Lau; Miguel A Cabrita; Emma Nolan; Peter A Crooks; Jane E Visvader; M A Christine Pratt
Journal:  Cell Stem Cell       Date:  2016-06-09       Impact factor: 24.633

9.  Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2.

Authors:  Suzanne A Hartford; Rajanikant Chittela; Xia Ding; Aradhana Vyas; Betty Martin; Sandra Burkett; Diana C Haines; Eileen Southon; Lino Tessarollo; Shyam K Sharan
Journal:  PLoS Genet       Date:  2016-08-04       Impact factor: 5.917

10.  RANKL/RANK control Brca1 mutation- .

Authors:  Verena Sigl; Kwadwo Owusu-Boaitey; Purna A Joshi; Anoop Kavirayani; Gerald Wirnsberger; Maria Novatchkova; Ivona Kozieradzki; Daniel Schramek; Nnamdi Edokobi; Jerome Hersl; Aishia Sampson; Ashley Odai-Afotey; Conxi Lazaro; Eva Gonzalez-Suarez; Miguel A Pujana; For Cimba; Holger Heyn; Enrique Vidal; Jennifer Cruickshank; Hal Berman; Renu Sarao; Melita Ticevic; Iris Uribesalgo; Luigi Tortola; Shuan Rao; Yen Tan; Georg Pfeiler; Eva Yhp Lee; Zsuzsanna Bago-Horvath; Lukas Kenner; Helmuth Popper; Christian Singer; Rama Khokha; Laundette P Jones; Josef M Penninger
Journal:  Cell Res       Date:  2016-05-31       Impact factor: 25.617

View more
  6 in total

Review 1.  BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer.

Authors:  Tzeh Keong Foo; Bing Xia
Journal:  Cancer Res       Date:  2022-09-16       Impact factor: 13.312

2.  Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice.

Authors:  Amar H Mahdi; Yanying Huo; Ying Chen; Pier Selenica; Anchal Sharma; Elise Merritt; Nicola Barnard; Chang Chan; Shridar Ganesan; Jorge S Reis-Filho; Britta Weigelt; Subhajyoti De; Bing Xia
Journal:  Genes Dis       Date:  2020-09-05

3.  Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.

Authors:  Hui Ma; Zhihua Kang; Tzeh Keong Foo; Zhiyuan Shen; Bing Xia
Journal:  Hepatology       Date:  2022-01-10       Impact factor: 17.298

4.  Tumor suppressor PALB2 maintains redox and mitochondrial homeostasis in the brain and cooperates with ATG7/autophagy to suppress neurodegeneration.

Authors:  Yanying Huo; Akshada Sawant; Yongmei Tan; Amar H Mahdi; Tao Li; Hui Ma; Vrushank Bhatt; Run Yan; Jake Coleman; Cheryl F Dreyfus; Jessie Yanxiang Guo; M Maral Mouradian; Eileen White; Bing Xia
Journal:  PLoS Genet       Date:  2022-04-11       Impact factor: 5.917

5.  Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development.

Authors:  Yanying Huo; Pier Selenica; Amar H Mahdi; Fresia Pareja; Kelly Kyker-Snowman; Ying Chen; Rahul Kumar; Arnaud Da Cruz Paula; Thais Basili; David N Brown; Xin Pei; Nadeem Riaz; Yongmei Tan; Yu-Xiu Huang; Tao Li; Nicola J Barnard; Jorge S Reis-Filho; Britta Weigelt; Bing Xia
Journal:  NPJ Breast Cancer       Date:  2021-04-23

Review 6.  Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast.

Authors:  Jessica S Helm; Ruthann A Rudel
Journal:  Arch Toxicol       Date:  2020-05-13       Impact factor: 5.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.